HLS Therapeutics (OTCMKTS:HLTRF) Price Target Cut to C$26.50

HLS Therapeutics (OTCMKTS:HLTRFGet Rating) had its target price cut by Clarus Securities from C$33.00 to C$26.50 in a research report issued to clients and investors on Wednesday, The Fly reports.

Separately, Canaccord Genuity Group cut their price target on HLS Therapeutics from C$30.75 to C$30.50 and set a “buy” rating on the stock in a research report on Friday, March 18th.

OTCMKTS HLTRF opened at $11.49 on Wednesday. The stock’s fifty day moving average price is $11.58 and its 200 day moving average price is $12.39. HLS Therapeutics has a 1 year low of $10.40 and a 1 year high of $16.44.

HLS Therapeutics Company Profile (Get Rating)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.

Featured Stories

The Fly logo

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.